In TIL-based ACT, naturally infiltrating lymphocytes are isolated from the resected tumor materials and ex vivo expanded in the presence of a high dose interleukin-2 (IL-2) to therapeutic numbers, or approximately 10-100 billion cells. The gene discussed is IL2; the disease is neoplasm.